Is more of a good thing still a good thing? PARP inhibitor retreatment in high-grade ovarian carcinoma

被引：0
|
作者：
McNeish, I. A. [1 ]
Monk, B. J. [2 ]
机构：
[1] Imperial Coll London, Ovarian Canc Act Res Ctr, Dept Surg & Canc, London, England
[2] Univ Arizona, HonorHlth Res Inst, Coll Med, Div Gynecol Oncol, Phoenix, AZ USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷 / 12期
关键词：
OLAPARIB MAINTENANCE THERAPY; DOUBLE-BLIND; OPEN-LABEL; CANCER; RUCAPARIB; PHASE-2; RESISTANCE; MULTICENTER; MUTATIONS;
D O I：
10.1016/j.annonc.2023.08.014
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1074 / 1076
页数：3
相关论文
共 50 条
  • [1] Personalising Treatment for High-Grade Serous Ovarian Carcinoma
    Cojocaru, E.
    Parkinson, C. A.
    Brenton, J. D.
    CLINICAL ONCOLOGY, 2018, 30 (08) : 515 - 524
  • [2] Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma
    Nesic, Ksenija
    Kondrashova, Olga
    Hurley, Rachel M.
    McGehee, Cordelia D.
    Vandenberg, Cassandra J.
    Ho, Gwo-Yaw
    Lieschke, Elizabeth
    Dall, Genevieve
    Bound, Nirashaa
    Shield-Artin, Kristy
    Radke, Marc
    Musafer, Ashan
    Chai, Zi Qing
    Ghamsari, Mohammad Reza Eftekhariyan
    Harrell, Maria, I
    Kee, Damien
    Olesen, Inger
    McNally, Orla
    Traficante, Nadia
    DeFazio, Anna
    Bowtell, David D. L.
    Swisher, Elizabeth M.
    Weroha, S. John
    Nones, Katia
    Waddell, Nicola
    Kaufmann, Scott H.
    Dobrovic, Alexander
    Wakefield, Matthew J.
    Scott, Clare L.
    CANCER RESEARCH, 2021, 81 (18) : 4709 - 4722
  • [3] Targeting DUSP Activity as a Treatment for High-Grade Serous Ovarian Carcinoma
    Sanders, Brooke E.
    Yamamoto, Tomomi M.
    McMellen, Alexandra
    Woodruff, Elizabeth R.
    Berning, Amber
    Post, Miriam D.
    Bitler, Benjamin G.
    MOLECULAR CANCER THERAPEUTICS, 2022, 21 (08) : 1285 - 1295
  • [4] Dual Targeting of CX3CR1 and PARP in Models of High-Grade Serous Ovarian Carcinoma
    Xie, Jia
    Barbolina, Maria V.
    CANCERS, 2024, 16 (22)
  • [5] High EVI1 and PARP1 expression as favourable prognostic markers in high-grade serous ovarian carcinoma
    Jank, Paul
    Leichsenring, Jonas
    Kolb, Svenja
    Hoffmann, Inga
    Bischoff, Philip
    Kunze, Catarina Alisa
    Dragomir, Mihnea P. P.
    Gleitsmann, Moritz
    Jesinghaus, Moritz
    Schmitt, Wolfgang D. D.
    Kulbe, Hagen
    Sers, Christine
    Stenzinger, Albrecht
    Sehouli, Jalid
    Braicu, Ioana Elena
    Westhoff, Christina
    Horst, David
    Denkert, Carsten
    Groeschel, Stefan
    Taube, Eliane T. T.
    JOURNAL OF OVARIAN RESEARCH, 2023, 16 (01)
  • [6] Clinical Outcomes of Patients with High-Grade Ovarian Carcinoma Arising in Endometriosis Compared to Ovarian High-Grade Serous Carcinoma
    Yalcin, Ibrahim
    Sahin, Hanifi
    Sari, Mustafa Erkan
    Haberal, Asuman Nihan
    Sahin, Eda Adeviye
    Celik, Husnu
    Meydanli, Mehmet Mutlu
    Ayhan, Ali
    INDIAN JOURNAL OF GYNECOLOGIC ONCOLOGY, 2021, 19 (04)
  • [7] Differential Sensitivity of Germline and Somatic BRCA Variants to PARP Inhibitor in High-Grade Serous Ovarian Cancer
    Vendrell, Julie A.
    Ban, Iulian O.
    Solassol, Isabelle
    Audran, Patricia
    Cabello-Aguilar, Simon
    Topart, Delphine
    Lindet-Bourgeois, Clothilde
    Colombo, Pierre-Emmanuel
    Legouffe, Eric
    D'Hondt, Veronique
    Fabbro, Michel
    Solassol, Jerome
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (18)
  • [8] Origin and molecular pathogenesis of ovarian high-grade serous carcinoma
    Kurman, R. J.
    ANNALS OF ONCOLOGY, 2013, 24 : 16 - 21
  • [9] Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas
    Bi, Yue
    Verginadis, Ioannis I.
    Dey, Souvik
    Lin, Lilie
    Guo, Linlang
    Zheng, Yanfang
    Koumenis, Constantinos
    GYNECOLOGIC ONCOLOGY, 2018, 150 (03) : 534 - 544
  • [10] Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma
    Watson, Zachary L.
    Yamamoto, Tomomi M.
    McMellen, Alexandra
    Kim, Hyunmin
    Hughes, Connor J.
    Wheeler, Lindsay J.
    Post, Miriam D.
    Behbakht, Kian
    Bitler, Benjamin G.
    CLINICAL EPIGENETICS, 2019, 11 (01)
12345